PT  - JOURNAL ARTICLE
AU  - Jelena Osmanovic Barilar
AU  - Ana Knezovic
AU  - Jan Homolak
AU  - Ana Babic Perhoc
AU  - Melita Salkovic-Petrisic
TI  - Divergent effect of central incretin receptors inhibition in a rat model of sporadic Alzheimer’s disease
AID  - 10.1101/2021.08.23.457308
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.08.23.457308
4099  - http://biorxiv.org/content/early/2021/08/24/2021.08.23.457308.short
4100  - http://biorxiv.org/content/early/2021/08/24/2021.08.23.457308.full
AB  - The incretin system is an emerging new field that might provide valuable contributions to the research of both pathophysiology and therapeutic strategies in the treatment of diabetes, obesity, and neurodegenerative disorders. This study aimed to explore the role of central glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) on cell metabolism and energy in the brain as well as on the levels of these incretins, insulin and glucose, by inhibiting the central incretins’ receptors following intracerebroventricular administration of the respective antagonists in healthy rats and a streptozotocin-induced rat model of sporadic Alzheimer’s disease (sAD). Chemical ablation of the central GIP receptor (GIPR) or GLP-1 receptor (GLP-1R) in healthy and diseased animals indicated a region-dependent role of incretins in the brain cell energy and metabolism and central incretin-dependent modulation of peripheral hormone secretion, markedly after GIPR inhibition, as well as a dysregulation of the GLP-1 system in experimental sAD.Competing Interest StatementThe authors have declared no competing interest.